Biosimilars

The AJMC^® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

By Cameron Santoro

December 20th 2024

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

AJMC

Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022

By Jingjing Qian, PhD

December 16th 2024

Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com

From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

By Skylar Jeremias

December 12th 2024

Health Policy. | Image Credit: Mohamad Zaki - stock.adobe.com

Policy Proposals Aim to Stimulate the Long-Term Sustainability of Infused Biosimilars

By Cameron Santoro

December 4th 2024

FDA approval. | Image Credit: syahrir - stock.adobe.com

FDA Approves Sixth Ustekinumab Biosimilar, Yesintek

By Skylar Jeremias

December 2nd 2024

More News

Dr Lee Schwartzberg on How Biosimilars Will Help Address Financial Toxicity

November 5th 2019

Dr Lee Schwartzberg on How Biosimilars Will Help Address Financial Toxicity

We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Tesh Khullar Highlights Changes That Will Impact Reimbursement for Biosimilars

November 3rd 2019

Tesh Khullar Highlights Changes That Will Impact Reimbursement for Biosimilars

Tesh Khullar, senior vice president & advisor, Flatiron Health, outlines changes that could impact community oncologists when it comes to reimbursement for biosimilars.

October 31st 2019

Preparing for the Near-Term Pipeline of Therapies, and Opportunities for Cost Savings

Laura Joszt, MA

Increased competition is making its way into the specialty drug market, affecting orphan conditions, cancer types, and even common specialty conditions, which is presenting some cost savings opportunities, explained Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts, who presented on the specialty pharmaceutical pipeline during her regular session at AMCP Nexus 2019.

October 29th 2019

Providers Move Forward With 2-Sided Risk and Take on Pharma

Heading into 2019, the idea that oncology practices would fully embrace financial responsibility for clinical decisions still seemed far-fetched for many. And yet, when it was time to make the call, moving to 2-sided risk proved a “simple” decision, said Travis Brewer of Texas Oncology, who took part in a panel offering an update on the Oncology Care Model (OCM) at the start of the Community Oncology Alliance (COA) Payer Exchange Summit, which opened Monday in Tyson’s Corner, Virginia.

Tesh Khullar Outlines Efforts Needed to Make Sure Providers Are Comfortable Prescribing Biosimilars

October 23rd 2019

Tesh Khullar Outlines Efforts Needed to Make Sure Providers Are Comfortable Prescribing Biosimilars

Tesh Khullar, senior vice president & advisor, Flatiron Health, explains what efforts are needed to make sure providers are comfortable prescribing biosimilars.

Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars

October 15th 2019

Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars

Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

September 29th 2019

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

September 27th 2019

Biosimilar Insulin Could Offer Patients Cost-Saving Options

Sara Karlovitch

From the Center for Biosimilars®, a discussion on giving patients new, less expensive alternatives for managing diabetes.

September 27th 2019

How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?

From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.

AJMC® in the Press, September 6, 2019

September 6th 2019

AJMC® in the Press, September 6, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

This Week in Managed Care: August 9, 2019

August 9th 2019

This Week in Managed Care: August 9, 2019

This week, the top managed care stories included CMS giving chimeric antigen receptor T-cell payments a boost; a US task force announcing that those at risk for pancreatic cancer should be screened; FDA revealing Novartis withheld data about a high-cost gene therapy.

AJMC® in the Press, August 9, 2019

August 9th 2019

AJMC® in the Press, August 9, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

July 16th 2019

Biosimilars: ASCO 2019

Research on biosimilars presented at the 2019 Annual Meeting of the American Society of Clinical Oncology.

AJMC® in the Press, June 21, 2019

June 21st 2019

AJMC® in the Press, June 21, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

May 23rd 2019

Biosimilar Experts Give Highlights of US Uptake Issues

Allison Inserro

During ISPOR 2019 annual meeting, a session featured biosimilar experts who reviewed the current state of affairs and various challenges related to uptake, while also sounding some notes of optimism.

What We're Reading: Measles Quarantines; Roche's Cancer Drug Competition; Blood Pressure Targets for T2D

April 29th 2019

What We're Reading: Measles Quarantines; Roche's Cancer Drug Competition; Blood Pressure Targets for T2D

Nearly 700 people at California State University and the University of California, both in Los Angeles, were still in quarantine over the weekend after possibly being exposed to measles; the world’s largest seller of cancer drugs, pharma company Roche Holding AG, will lose its top spot with competition from lower-cost drugs, namely biosimilars; findings from a new study showed that blood pressure regulation at or below 130/80 mm Hg lowered the risk of heart attack, stroke, or other complications in patients with type 2 diabetes (T2D).

April 17th 2019

Conference Coverage: NCCN Policy Updates

Jaime Rosenberg Mary Caffrey Laura Joszt, MA

Policy updates from the National Comprehensive Cancer Network's annual meeting.

AJMC® in the Press, April 5, 2019

April 5th 2019

AJMC® in the Press, April 5, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Dr Ali McBride Discusses the Role of Biosimilars in Oncology

March 25th 2019

Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved

March 24th 2019

Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved

Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.

AJMC® in the Press, March 22, 2019

March 22nd 2019

AJMC® in the Press, March 22, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

AJMC® in the Press, March 8, 2019

March 8th 2019

AJMC® in the Press, March 8, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

What We're Reading: Canada Sets Biologics Naming Rules; Heath Trackers and Employee Privacy; IVF and Embryos

February 18th 2019

What We're Reading: Canada Sets Biologics Naming Rules; Heath Trackers and Employee Privacy; IVF and Embryos

Health Canada announced that all biologics, including biosimilars, will be identified by their brand names and nonproprietary names without the addition of a product-specific suffix; a boom in the use of connected health and fitness monitors that are connected to insurance plans and employers is providing an increasingly valuable source of workforce health intelligence, raising privacy concerns, and adding a new dimension to the worker-employer relationship; as the number of spare embryos from in vitro fertilization rises, giving birth with donated embryos is becoming more popular, although many of the agencies that provide donated embryos are supported by federal funds and restrict whom they help.

What We're Reading: Drug Pricing Proposals; Idaho Medicaid Expansion; Business and Biosimilars

January 25th 2019

What We're Reading: Drug Pricing Proposals; Idaho Medicaid Expansion; Business and Biosimilars

Presumed 2020 presidential candidates are trying to stake a claim to one of healthcare’s main concerns—surging prescription drug prices; enrollment in Idaho's health insurance exchange is expected to drop by 20% due to Medicaid expansion; employer groups can help overcome barriers, such as patient fears and misinformation, and create confidence about using biosimilars.

Dr Robert Rifkin on Lack of Education Surrounding Biosimilars

January 22nd 2019

Dr Robert Rifkin on Lack of Education Surrounding Biosimilars

Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.

January 18th 2019

Cost of Care: Biosimilars

Updates from the annual ASH meeting, December 2018.

What We're Reading: Faulty Drugs; Biosimilar Awareness; Maine Implements Medicaid

January 4th 2019

What We're Reading: Faulty Drugs; Biosimilar Awareness; Maine Implements Medicaid

A review of thousands of FDA inspection records, recalls, warning letters, and lawsuits showed how drugs that are poorly manufactured or contaminated can reach patients; biosimilars have the potential to deliver substantial savings to the healthcare system, but only insofar as they are adopted and used in clinical practice; Maine’s new Democratic Governor, Janet Mills, ordered the state to implement Medicaid expansion with an executive order, calling for state health officials to make the necessary changes and work with the Trump administration.

The Key Biosimilars Developments of 2018

December 21st 2018

The Key Biosimilars Developments of 2018

The year 2018 was a banner year for biosimilars, with the number of FDA-approved biosimilar products nearly doubling, and with major policy, business, and regulatory developments that moved the biosimilars marketplace forward. Here are 5 of the top developments in biosimilars for the past year, as reported by The Center for Biosimilars®, a sister site of The American Journal of Managed Care®.

December 12th 2018

Biosimilars Updates

Kelly Davio Samantha DiGrande

What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption

December 12th 2018

What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption

The House has passed a bill that would support state efforts to investigate pregnancy-related deaths and research how to prevent future deaths; a column in The New York Times examined 4 specific drug pricing policies and had 3 health policy experts weigh in on what the outcomes of implementing these policies could be; despite the benefits of using biosimilar filgrastim, the United States has lagged behind other countries in adopting the therapy.

...

8 9 10 11 12 13 14 15 16

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions